We wish you to inform you that the Board of Directors of Asarfi Hospital Limited at its meeting held on November 10,2025 has considered and approved the unaudited financial Results of the ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Asarfi Hospital Limited's board approved unaudited H1 FY26 results on November 10, 2025, with an unmodified (clean) opinion from statutory auditors R. K. Thakkar & Co. Standalone revenue from operations for H1 FY26 came in at ₹80.51 crore, with Q2 FY26 alone delivering ₹44.85 crore (up ~45% YoY from ₹30.86 crore in Q2 FY25). Standalone profit after tax for H1 FY26 was ₹7.50 crore, with Q2 PAT of ₹4.30 crore (up ~48% YoY from ₹2.90 crore). EPS rose to ₹3.81 (H1 FY26) versus ₹2.19 in the prior comparable period. The company also availed a fresh ₹4.68 crore SBI term loan for a new Cath Lab at the Dhanbad hospital and a ₹2 crore bank guarantee limit for corporate/PSU empanelments. Operating cash flow swung positive to ₹9.28 crore (standalone) from a negative ₹3.84 crore in FY25.
Strong double-digit YoY growth in both revenue and profit signals healthy operational momentum and likely positive sentiment for shareholders; new SBI-backed borrowings for a Cath Lab and corporate empanelments support future capacity and revenue, though it adds modest leverage (debt/equity around 0.37).